Physiomics awarded further contracts with Bicycle Therapeutics and Merck
Oncology consultancy Physiomics has been awarded further contracts of an undisclosed value for projects with existing clients Bicycle Therapeutics and Merck.
Physiomics said the project with Bicycle was the eighth it had signed with the UK biotech company, spanning four different assets within its pipeline, and involved population pharmacokinetic analysis of clinical data.
The AIM-listed group added that the project with Merck was an extension of one previously announced and was now in the third year of work under the pair's master services agreement, announced in November 2017.
Physiomics anticipates that both projects will be completed over the next four months.
As of 0930 BST, Physiomics shares were up 3.70% at 7.0p.